Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Income Statement [Abstract]
Revenue	$ 48,556	$ 50,974	$ 91,168	$ 93,340
Cost of goods sold	16,332	21,515	30,302	35,940
Gross profit	32,224	29,459	60,866	57,400
Operating expenses:
Research and development	5,734	7,714	11,264	15,559
Clinical and regulatory affairs	2,740	4,022	6,575	7,905
Marketing and sales	23,781	28,824	49,681	56,742
General and administrative	7,904	10,210	16,777	20,156
Restructuring costs	(29)	790	137	8,114
Settlement costs	0	0	0	4,650
Contract termination and business acquisition expenses	0	1,127	0	5,905
Total operating expenses	40,130	52,687	84,434	119,031
Loss from operations	(7,906)	(23,228)	(23,568)	(61,631)
Other income (expense):
Interest income	28	48	72	110
Interest expense	(5,803)	(3,815)	(10,098)	(7,597)
Other income (expense), net	223	(556)	176	(912)
Change in fair value of contingent consideration related to acquisition	3,800	(100)	2,600	(100)
Loss on debt extinguishment	(6,512)	0	(6,512)	0
Change in fair value of derivative liabilities	0	(38,743)	0	(43,831)
Total other income (expense)	(8,264)	(43,166)	(13,762)	(52,330)
Net loss before income tax expense	(16,170)	(66,394)	(37,330)	(113,961)
Income tax expense	(122)	(443)	(276)	(546)
Net loss	(16,292)	(66,837)	(37,606)	(114,507)
Other comprehensive income (loss) foreign currency translation	781	1,019	1,137	914
Comprehensive loss	$ (15,511)	$ (65,818)	$ (36,469)	$ (113,593)
Basic and diluted net loss per share (in dollars per share)	$ (0.20)	$ (0.81)	$ (0.45)	$ (1.44)
Shares used in computing basic and diluted net loss per share (in shares)	83,247	82,072	83,087	79,368